Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Coronavirus Update:What patients and families need to know

Tissue Engineered Model of Preeclampsia

Image banner for Tissue Engineered pre-ecllampsia project

Key Personnel

  • John Fisher, PhD 
  • Che-Ying (Vincent) Kuo, MS, PhD Candidate 
  • Peter Kim, MD, PhD

Using 3D printing technologies, we hypothesize that we can fabricate a vascularized tissue model with heterogeneous ECM, growth factor composition/concentration, and cellular compositions to develop in vitro models for disease such as preeclampsia (PE).  PE is the leading cause of maternal and fetal morbidity and mortality, and affects 5 percent of all pregnancies. There is a lack of treatment options and understanding of PE compared to other multifactorial diseases such as heart and kidney diseases. This is partly due to the lack of appropriate experimental models for treatment development. We will test our hypothesis by the following: identify the appropriate printing parameters and biomaterials/cells to develop a 3D tissue engineered model of placenta; place the placenta model under dynamic culture conditions and evaluate the effect of soluble factors on the morphologies, viabilities, and phenotypes of human villous trophoblast, endothelial cells, and epithelial cells; and demonstrate the potential of the tissue-engineered invasion model as a drug-screening and disease-modeling tool by applying the strategy to preeclampsia.